Trial Profile
Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPD.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 20 Sep 2023
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary) ; Fluticasone propionate
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- 25 Mar 2014 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.
- 05 Oct 2010 New trial record